Role of complement and complement regulatory proteins in the complications of diabetes

Endocrine Reviews

Volumn 36, Issue 3, 2015, Pages 272-288

  Ghosh, Pamela ^a   Sahoo, Rupam ^a   Vaidya, Anand ^a   Chorev, Michael ^a   Halperin, Jose A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; REGULATOR PROTEIN;

CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENZYME ACTIVITY; GLYCATION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REVIEW; TARGET ORGAN; UPREGULATION; ANIMAL; DIABETIC ANGIOPATHY; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, CD59; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; DIABETIC ANGIOPATHIES; HUMANS;

EID: 84931312316     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2014-1099     Document Type: Review

References (185)

1. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894-903.
2. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47:1703-1720.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
4. Pedersen O, Gaede P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism. 2003;52:19-23.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-1070.
7. Brownlee M. The pathobiology of diabetic complications:a unifying mechanism. Diabetes. 2005;54:1615-1625.
8. Acosta J, Hettinga J, Flückiger R, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad SciUSA. 2000;97:5450-5455.
9. Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N, Hays AP. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol (Berl). 2000;99:55-62.
10. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol- anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes. 2002;51:3499-3504.
11. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol. 2010;6:94-101.
12. Mellbin LG, Bjerre M, Thiel S, Hansen TK. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care. 2012;35:911-917.
13. Hansen TK, Tarnow L, Thiel S, et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes. 2004;53:1570-1576.
14. Hansen TK. Mannose-binding lectin (MBL) and vascular complications in diabetes. Horm Metab Res. 2005; 37(suppl 1):95-98.
15. Hansen TK, Forsblom C, Saraheimo M, et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia. 2010;53:1517-1524.
16. Hovind P, Hansen TK, Tarnow L, et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes:an inception cohort study. Diabetes. 2005;54:1523-1527.
17. Uesugi N, Sakata N, Nangaku M, et al. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy:glycoxidation-mediated local complement activation. Am J Kidney Dis. 2004;44:224-238.
18. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes. 2011;60:2354-2369.
19. Qin X, Goldfine A, Krumrei N, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes. 2004;53:2653-2661.
20. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. 2005; 54:570-575.
21. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period:the CODAM study. Diabetes Care. 2014;37:1900-1909.
22. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol. 2010;128:349-358.
23. Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2002;43:1104-1108.
24. Hertle E, Stehouwer CD, van Greevenbroek MM. The complement system in human cardiometabolic disease. Mol Immunol. 2014;61:135-148.
25. Morgan BP, Gasque P. Extrahepatic complement biosynthesis:where, when and why? Clin Exp Immunol. 1997; 107:1-7.
26. Laufer J, Katz Y, Passwell JH. Extrahepatic synthesis of complement proteins in inflammation. Mol Immunol. 2001;38:221-229.
27. Andoh A, Fujiyama Y, Sakumoto H, et al. Detection of complement C3 and factor B gene expression in normal colorectal mucosa, adenomas and carcinomas. Clin Exp Immunol. 1998;111:477-483.
28. Passwell JH, Schreiner GF, Wetsel RA, Colten HR. Complement gene expression in hepatic and extrahepatic tissues of NZB and NZB x W (F1) mouse strains. Immunology. 1990;71:290-294.
29. Morgan BP, Harris CL. Complement Regulatory Proteins. London, UK: Academic Press; 1999.
30. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-1066.
31. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140-1144.
32. Halperin JA, Taratuska A, Rynkiewicz M, Nicholson-Weller A. Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood. 1993;81:200-205.
33. Acosta JA, Benzaquen LR, Goldstein DJ, Tosteson MT, Halperin JA. The transient pore formed by homologous terminal complement complexes functions as a bidirectional route for the transport of autocrine and paracrine signals across human cell membranes. Mol Med. 1996;2:755-765.
34. Halperin JA, Nicholson-Weller A, Brugnara C, Tosteson DC. Complement induces a transient increase in membrane permeability in unlysed erythrocytes. J Clin Invest. 1988;82:594-600.
35. Halperin JA, Brugnara C, Nicholson-Weller A. Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes. J Clin Invest. 1989;83:1466-1471.
36. Berger HJ, Taratuska A, Smith TW, Halperin JA. Activated complement directly modifies the performance of isolated heart muscle cells from guinea pig and rat. Am J Physiol. 1993;265:H267-H272.
37. Nicholson-Weller A, Halperin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res. 1993;12:244-257.
38. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity.AnnuRev Immunol. 1998;16:545-568.
39. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179:985-992.
40. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 1996; 16:673-677.
41. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264:9053-9060.
42. Marks RM, Todd RF 3rd, Ward PA. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature. 1989;339:314-317.
43. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868-874.
44. Kostner KM. Activation of the complement system: a crucial link between inflammation and atherosclerosis? Eur J Clin Invest. 2004;34:800-802.
45. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809-3814.
46. Christiansen VJ, Sims PJ, Hamilton KK. Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:164-171.
47. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995;182:1807-1814.
48. Wu G, Hu W, Shahsafaei A, et al. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res. 2009;104:550-558.
49. Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011;51:45-60.
50. Morgan BP, Campbell AK. The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem J. 1985;231:205-208.
51. Adler S, Baker PJ, Johnson RJ, Ochi RF, Pritzl P, Couser WG. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest. 1986;77:762-767.
52. Bellosillo B, Villamor N, López-Guillermo A, et al. Complement- mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98:2771-2777.
53. Cybulsky AV, Bonventre JV, Quigg RJ, Lieberthal W, Salant DJ. Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury. Kidney Int. 1990;38:803-811.
54. Carney DF, Lang TJ, Shin ML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol. 1990;145:623-629.
55. Niculescu F, Rus H, Shin ML. Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J Biol Chem. 1994; 269:4417-4423.
56. Niculescu F, Rus H, van Biesen T, Shin ML. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes isGprotein dependent. J Immunol. 1997;158:4405-4412.
57. Niculescu F, Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res. 2001;24:191-199.
58. Kilgore KS, Schmid E, Shanley TP, et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-α B activation. Am J Pathol. 1997;150:2019-2031.
59. Viedt C, Hänsch GM, Brandes RP, Kübler W, Kreuzer J. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-κ B and AP-1. FASEB J. 2000;14:2370-2372.
60. Torbohm I, Schönermark M, Wingen AM, Berger B, Rother K, Hänsch GM. C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells. Kidney Int. 1990;37:1098-1104.
61. Lovett DH, Haensch GM, Goppelt M, Resch K, Gemsa D. Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol. 1987;138:2473-2480.
62. Stahl RA, Thaiss F, Disser M, Helmchen U, Hora K, Schlöndorff D. Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int. 1993;44:1036-1047.
63. Wagner C, Braunger M, Beer M, Rother K, Hänsch GM. Induction of matrix protein synthesis in human glomerular mesangial cells by the terminal complement complex. Exp Nephrol. 1994;2:51-56.
64. Kotajima N, Kimura T, Kanda T, et al. Type IV collagen as an early marker for diabetic nephropathy in non-insulindependent diabetes mellitus. J Diabetes Complications. 2000;14:13-17.
65. Adler SG, Feld S, Striker L, et al. Glomerular type IV collagen in patients with diabetic nephropathy with and without additional glomerular disease. Kidney Int. 2000;57:2084-2092.
66. Kooyman DL, Byrne GW, McClellan S, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science. 1995;269:89-92.
67. Morgan BP. Complement regulatory molecules: application to therapy and transplantation. Immunol Today. 1995;16:257-259.
68. Ninomiya H, Sims PJ. The human complement regulatory protein CD59 binds to the α-chain of C8 and to the "b"domain of C9. J Biol Chem. 1992;267:13675-13680.
69. Kimberley FC, Sivasankar B, Paul Morgan B. Alternative roles for CD59. Mol Immunol. 2007;44:73-81.
70. Lin RC, Herman J, Henry L, Daniels GL. Afamily showing inheritance of the Inab phenotype. Transfusion. 1988;28:427-429.
71. Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood. 1989;74:437-441.
72. Reid ME, Mallinson G, Sim RB, et al. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood. 1991;78:3291-3297.
73. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA. 1999;96:628-633.
74. Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990;323:1184-1189.
75. Nevo Y, Ben-Zeev B, Tabib A, et al. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood. 2013;121:129-135.
76. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. CurrOpinHematol. 1996; 3:101-110.
77. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318-1320.
78. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993; 73:703-711.
79. Miyata T,YamadaN, Iida Y, et al. Abnormalities ofPIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330:249-255.
80. Halperin JA, Nicholson-Weller A. Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease. Complement Inflamm. 1989;6:65-72.
81. Parker CJ. Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells. 1996;14:396-411.
82. Falk RJ, Dalmasso AP, Kim Y, et al. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest. 1983;72:560-573.
83. Falk RJ, Scheinman JI, Mauer SM, Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes. 1983;32(suppl 2):34-39.
84. Falk RJ, Sisson SP, Dalmasso AP, Kim Y, Michael AF, Vernier RL. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis. 1987;9:121-128.
85. Bouwman LH, Eerligh P, Terpstra OT, et al. Elevated levels of mannose-binding lectin at clinical manifestation of type 1 diabetes in juveniles. Diabetes. 2005;54:3002-3006.
86. Hansen TK, Thiel S, Knudsen ST, et al. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab. 2003;88:4857-4861.
87. Saraheimo M, Forsblom C, Hansen TK, et al. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia. 2005; 48:198-202.
88. Kaunisto MA, Sjölind L, Sallinen R, et al. Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy. Diabetes. 2009;58:1710-1714.
89. Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol. 2010;223:5-12.
90. Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008;19:478-482.
91. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol. 1999;36:949-955.
92. Lappegård KT, Garred P, Jonasson L, et al. A vital role for complement in heart disease. Mol Immunol. 2014;61:126-134.
93. Niculescu F, Rus HG, Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol. 1987;45:147-155.
94. Pang AS, Katz A, Minta JO. C3 deposition in cholesterolinduced atherosclerosis in rabbits: a possible etiologic role for complement in atherogenesis. J Immunol. 1979;123:1117-1122.
95. Schmiedt W, Kinscherf R, Deigner HP, et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998;18:1790-1795.
96. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest. 1989;60:747-754.
97. Seifert PS, Kazatchkine MD. The complement system in atherosclerosis. Atherosclerosis. 1988;73:91-104.
98. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
99. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22:79-84.
100. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412:1171-1179.
101. Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia. 2012;55:881-884.
102. Cianflone K, Xia Z, Chen LY. Critical review of acylationstimulating protein physiology in humans and rodents. Biochim Biophys Acta. 2003;1609:127-143.
103. Fortpied J, Vertommen D, Van Schaftingen E. Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes. Diabetes Metab Res Rev. 2010;26:254-260.
104. Ostergaard JA, Bjerre M, Dagnaes-Hansen F, Hansen TK, Thiel S, Flyvbjerg A. Diabetes-induced changes in mannanbinding lectin levels and complement activation in a mouse model of type 1 diabetes. Scand J Immunol. 2013;77:187-194.
105. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-VirellaMF. Antibodies to oxidizedLDLpredict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1999;48:1454-1458.
106. Witztum JL, Steinbrecher UP, Fisher M, Kesaniemi A. Nonenzymatic glucosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guinea pig. Proc Natl Acad Sci USA. 1983;80:2757-2761.
107. Weiss JS, Sang DN, Albert DM. Immunofluorescent characteristics of the diabetic cornea. Cornea. 1990;9:131-138.
108. Shapiro R, McManus MJ, Zalut C, Bunn HF. Sites of nonenzymatic glycosylation of human hemoglobin A. J Biol Chem. 1980;255:3120-3127.
109. Iberg N, Flückiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem. 1986;261:13542-13545.
110. Shilton BH, Walton DJ. Sites of glycation of human and horse liver alcohol dehydrogenase in vivo. J Biol Chem. 1991;266:5587-5592.
111. Shilton BH, Campbell RL, Walton DJ. Site specificity of glycation of horse liver alcohol dehydrogenase in vitro. Eur J Biochem. 1993;215:567-572.
112. Calvo C, Ulloa N, Campos M, Verdugo C, Ayrault-Jarrier M. The preferential site of non-enzymatic glycation of human apolipoprotein A-I in vivo. Clin Chim Acta. 1993; 217:193-198.
113. Flückiger R, Strang CJ. Structural requirements for protein glycation. Protein Sci. 1995;4:699S.
114. Fletcher CM, Harrison RA, Lachmann PJ, Neuhaus D. Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure. 1994;2:185-199.
115. Bodian DL, Davis SJ, Morgan BP, Rushmere NK. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med. 1997;185:507-516.
116. YuJ, Abagyan R, Dong S, Gilbert A, Nussenzweig V,Tomlinson S. Mapping the active site of CD59. J Exp Med. 1997;185:745-753.
117. Vischer UM. Hyperglycemia and the pathogenesis of atherosclerosis:lessons from murine models. Eur J Endocrinol. 1999;140:1-3.
118. Hsueh W, Abel ED, Breslow JL, et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res. 2007;100:1415-1427.
119. Brosius FC 3rd, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J AmSoc Nephrol. 2009; 20:2503-2512.
120. An G, Miwa T, Song WL, et al. CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice. Mol Immunol. 2009;46:1702-1709.
121. Buono C, Come CE, Witztum JL, et al. Influence of C3 deficiency on atherosclerosis. Circulation. 2002;105:3025-3031.
122. Liu F, Ge X, Sahoo R, Qin X, Halperin J. The deficiency of CD59 accelerates the development of diabetic atherosclerosis in mice. Mol Immunol. 2014;61:223.
123. Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML. Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med. 1977;86:425-429.
124. Bern MM, Busick EJ. Disorders of the blood and diabetes. In: Marble A, Krall L, Bradley R, Chistlieb A, Soeldner J, eds. Joslin's Diabetes Mellitus. Philadelphia, PA: Lea & Febiger; 1985:748.
125. Giugliano D. Glycosylated haemoglobin and reticulocyte count in diabetes. Diabetologia. 1982;22:223.
126. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15:44-54.
127. Gardner FH, Robin ED, Travis DM, Julian DG, Crump CH. Some pathophysiologic aspects of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1958;37:895.
128. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985-4996; quiz 5105.
129. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192-1196.
130. Qin X, Hu W, Song W, et al. Balancing role of nitric oxide in complement-mediated activation of platelets from mCd59a and mCd59b double-knockout mice. Am J Hematol. 2009;84:221-227.
131. Qin X, Hu W, Song W, et al. Generation and phenotyping of mCd59a and mCd59b double-knockout mice.AmJ Hematol. 2009;84:65-70.
132. Qin X, Krumrei N, Grubissich L, et al. Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity. 2003;18:217-227.
133. Meri S, Lehto T, Sutton CW, Tyynelä J, Baumann M. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J. 1996; 316:923-935.
134. Lehto T, Meri S. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8. J Immunol. 1993;151:4941-4949.
135. Lehto T, Honkanen E, Teppo AM, Meri S. Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int. 1995;47:1403-1411.
136. Väkevä A, Lehto T, Takala A, Meri S. Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction. Scand J Immunol. 2000;52:411-414.
137. Ghosh P, Sahoo R, Vaidya A, et al. A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes. Am J Hematol. 2013;88:670-676.
138. Ghosh P, Vaidya A, Sahoo R, et al. Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab. 2014;99:E999-E1006.
139. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014;123:3733-3738.
140. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25:1265-1275.
141. Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol. 2013;735:1-22.
142. Forneris F, Ricklin D, Wu J, et al. Structures of C3b in complex with factors B andDgive insight into complement convertase formation. Science. 2010;330:1816-1820.
143. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature. 2006;444:213-216.
144. Janssen BJ, Huizinga EG, Raaijmakers HC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature. 2005; 437:505-511.
145. Torreira E, Tortajada A, Montes T, Rodríguez de Córdoba S, Llorca O. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci USA. 2009;106:882-887.
146. Wiesmann C, Katschke KJ, Yin J, et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature. 2006;444:217-220.
147. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10:728-733.
148. Rooijakkers SH, Wu J, Ruyken M, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol. 2009;10:721-727.
149. Garlatti V, Chouquet A, Lunardi T, et al. Cutting edge:C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain. J Immunol. 2010; 185:808-812.
150. Laursen NS, Gordon N, Hermans S, et al. Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus. Proc Natl Acad Sci USA. 2010; 107:3681-3686.
151. Shaw CD, Storek MJ, Young KA, et al. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol. 2010;404:697-710.
152. Gingras AR, Girija UV, Keeble AH, et al. Structural basis of mannan-binding lectin recognition by its associated serine protease MASP-1: implications for complement activation. Structure. 2011;19:1635-1643.
153. Kajander T, Lehtinen MJ, Hyvärinen S, et al. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci USA. 2011;108:2897-2902.
154. Morgan HP, Schmidt CQ, Guariento M, et al. Structural basis for engagement by complement factorHof C3b on a self surface. Nat Struct Mol Biol. 2011;18:463-470.
155. van den Elsen JM, Isenman DE. A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science. 2011;332:608-611.
156. Hadders MA, Bubeck D, Roversi P, et al. Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Reports. 2012;1:200-207.
157. Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet. 2011;88:689-705.
158. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.
159. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123-4128.
160. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256-1264.
161. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169-2181.
162. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2000;108:470-479.
163. Risitano AM. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology. 2012;217:1080-1087.
164. Lanting LC, Joung IM, Mackenbach JP, Lamberts SW, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of careamongdiabetic patients:a review. Diabetes Care. 2005;28:2280-2288.
165. Matsushita M, Endo Y, Nonaka M, Fujita T. Complement- related serine proteases in tunicates and vertebrates. Curr Opin Immunol. 1998;10:29-35.
166. Podack ER. Molecular composition of the tubular structure of the membrane attack complex of complement. J Biol Chem. 1984;259:8641-8647.
167. Podack ER, Müller-Eberhard HJ, Horst H, Hoppe W. Membrane attach complex of complement (MAC): threedimensional analysis of MAC-phospholipid vesicle recombinants. J Immunol. 1982;128:2353-2357.
168. Podack ER, Tschopp J. Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci USA. 1982; 79:574-578.
169. Podack ER, Tschopp J. Membrane attack by complement. Mol Immunol. 1984;21:589-603.
170. Tschopp J, Engel A, Podack ER. Molecular weight of poly(C9). 12 to 18 C9 molecules form the transmembrane channel of complement. J Biol Chem. 1984;259:1922-1928.
171. Laine RO, Esser AF. Detection of refolding conformers of complement protein C9 during insertion into membranes. Nature. 1989;341:63-65.
172. Mayer MM. Complement. Historical perspectives and some current issues. Complement. 1984;1:2-26.
173. Ramm LE, Whitlow MB, Mayer MM. Transmembrane channel formation by complement: functional analysis of the number of C5b6, C7, C8, and C9 molecules required for a single channel. Proc Natl Acad Sci USA. 1982;79:4751-4755.
174. Ramm LE, Whitlow MB, Mayer MM. The relationship between channel size and the number of C9 molecules in the C5b-9 complex. J Immunol. 1985;134:2594-2599.
175. Nicholson-Weller A, March JP, Rosen CE, Spicer DB, Austen KF. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood. 1985; 65:1237-1244.
176. Brooimans RA. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement mediated lysis. Eur J Immunol. 1992;22:3135-3140.
177. Cervoni F, Oglesby TJ,AdamsEM,et al. Identification and characterization of membrane cofactor protein of human spermatozoa. J Immunol. 1992;148:1431-1437.
178. Beynon HL, Davies KA, Haskard DO, Walport MJ. Erythrocyte complement receptor type 1 and interactions between immune complexes, neutrophils, and endothelium. J Immunol. 1994;153:3160-3167.
179. McDonald JF, Nelsestuen GL. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. Biochemistry. 1997;36:7464-7473.
180. Podack ER, Müller-Eberhard HJ. Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol. 1978;121:1025-1030.
181. Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989;170:637-654.
182. Huang Y, Qiao F, Abagyan R, Hazard S, Tomlinson S. Defining the CD59-C9 binding interaction. J Biol Chem. 2006;281:27398-27404.
183. Hüsler T, Lockert DH, Kaufman KM, Sodetz JM, Sims PJ. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59. J Biol Chem. 1995;270:3483-3486.
184. Meri S, Morgan BP, Wing M, et al. Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis. J Exp Med. 1990;172:367-370.
185. Petranka JG, Fleenor DE, Sykes K, Kaufman RE, Rosse WF. Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci USA. 1992;89:7876-7879.